On February 28, 2023 Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, reported that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Administration (TGA) in Australia (Press release, Mabwell Biotech, FEB 28, 2023, View Source [SID1234627938]). 9MW3811 is the first IL-11 targeting monoclonal antibody approved to clinical study at present.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

9MW3811 is an innovative humanized monoclonal antibody against IL-11, which can bind IL-11 through high affinity and effectively block the activation of IL-11 downstream signal pathway being developed for fibrosis and oncology.

9MW3811 is first IL-11-targeting monoclonal antibody and first non recombinant protein drug candidate targeting IL-11 approved to clinical study as well.